C

Center for Neurosciences | Tucson, AZ

Research site
(Unclaimed)
Location
2450 E. River Road, Tucson, Arizona, United States of America

Site insights

Top conditions

Top treatments

Aducanumab
Temozolomide
Teriflunomide
Droxidopa
Pregabalin
Solanezumab
BHV-7000
Eslicarbazepine Acetate
Bevacizumab
LY573144

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

21 of 45 total trials

A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS2)

The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of m...

Enrolling
Migraine
Drug: Lasmiditan

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).

Enrolling
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

This clinical trial is testing the safety and efficacy of NanO2TM administered via intravenous infusion in combination with standard radiation and ch...

Enrolling
Glioblastoma Multiforme
Drug: Placebo Saline Infusion
Drug: NanO2TM

A phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and safety of AL002 in participants with Early Alzheimer's Disea...

Active, not recruiting
Alzheimer Disease
Drug: Placebo
Drug: AL002

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participant...

Enrolling
Chronic Migraine
Drug: Galcanezumab
Drug: Placebo

The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatme...

Enrolling
Episodic Migraine
Drug: Placebo
Drug: Galcanezumab

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks an...

Enrolling
Migraine
Drug: Placebo
Drug: Lasmiditan

The main aim of the study is to learn if soticlestat, when given as an add-on therapy, reduces the number of seizures in children and adults with Dra...

Enrolling
Dravet Syndrome (DS)
Lennox Gastaut Syndrome (LGS)
Drug: Soticlestat

The aims of the study are:* to learn if soticlestat, when given as add-on therapy, reduces the number of major motor drop seizures in children, teena...

Active, not recruiting
Lennox Gastaut Syndrome (LGS)
Drug: Placebo
Drug: Soticlestat
Status recently updated

The purpose of this study is to determine whether BHV-7000 is effective in the treatment of idiopathic generalized epilepsy with generalized tonic-cl...

Not yet enrolling
Enrolling
Generalized Epilepsy
Drug: Placebo
Drug: BHV-7000
Locations recently updated

The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.

Enrolling
Focal Epilepsy
Drug: BHV-7000
Drug: Placebo

The purpose of the study is to evaluate the efficacy of perampanel as measured by the 50 percent (%) responder rate during the maintenance period of...

Enrolling
Partial-onset Seizures
Pediatric Epileptic Syndrome
Drug: Perampanel Oral Suspension
Drug: Perampanel Tablet

The primary objective is to evaluate the safety and tolerability of aducanumab over 100 weeks of treatment after a wash-out period imposed by discont...

Active, not recruiting
Alzheimer's Disease
Drug: Aducanumab

A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible parti...

Active, not recruiting
Relapsing Multiple Sclerosis
Drug: Placebo
Drug: Fenebrutinib

This is a randomized, double blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and pharmacokinetics of a higher dose...

Active, not recruiting
Multiple Sclerosis
Drug: Ocrelizumab
Drug: Methylprednisolone

This is a two-part, multicenter, double-blind, parallel-group, placebo controlled study to evaluate the effect of ZX008 when used as adjunctive thera...

Active, not recruiting
Lennox Gastaut Syndrome
Drug: Matching Placebo
Drug: ZX008 0.2 or 0.8 mg/kg/day

This is an international, multicenter, open-label, long-term safety study of ZX008 in subjects with Dravet syndrome, Lennox-Gastaut syndrome or epile...

Active, not recruiting
Epileptic Encephalopathy
Dravet Syndrome
Drug: ZX008 (Fenfluramine Hydrochloride)

In this study, researchers will learn more about a study drug called BIIB080. The study will focus on participants with mild cognitive impairment or...

Enrolling
Mild Cognitive Impairment Due to Alzheimer's Disease
Alzheimer's Disease Dementia
Drug: BIIB080-matching placebo
Drug: BIIB080

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)

Enrolling
Relapsing Multiple Sclerosis
Drug: Teriflunomide
Drug: Remibrutinib

Trial sponsors

Lilly logo
Biogen logo
Roche logo
Sumitomo Pharma logo
Biohaven logo
N
Takeda logo
Viatris logo
A
AstraZeneca logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems